secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELITE PHARMACEUTICALS INC /NV/ (ELTP)
CIK:        0001053369
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001493152-24-032412
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elite Pharma Q1 FY2025 revenue up 109% YoY to $18.8M; operating profit +144%
----------------------------------------------------------------------------

- Revenue of $18.8M for Q1 ended June 30, 2024, compared to $9.0M in Q1 FY2024.
- Operating profit rose to $3.9M from $1.6M YoY, a 144% increase.
- Net income attributable to common shareholders was $0.6M.
- Growth driven by higher sales of Elite label product line.
- Conference call scheduled for August 15, 2024 at 11:30 AM EDT.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053369/000149315224032412/0001493152-24-032412-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053369/000149315224032412/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-032412

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer